All In Biotech

Drug Trial Radar · NCT05651932

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Feb 22, 2023

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
K36 Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Dec 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

Conditions

  • Multiple Myeloma
  • Myeloma
  • Myeloma Multiple

Interventions

  • Cohort A1 & A2: KTX-1001Drug

    KTX-1001: Orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly

  • Cohort B1 & B2: KTX-1001+MezigdomideDrug

    Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Mezigdomide Dexamethasone: Orally once weekly

  • Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)Drug

    Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle

  • Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)Drug

    Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once a week Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Determination of Recommended Phase 2 Dose (RP2D) and/or Maximum Tolerated Dose (MTD) Dose Expansion: Provide preliminary efficacy data on the antitumor effects of KTX-1001 in combination with other anti-myeloma therapyTime frame: Cycle 1 (28 days)

Locations

29 sites in 4 countries. Site status is shown where the registry gives one.

  • UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic

    San Francisco, California · Recruiting

  • Mayo Clinic Hospital - Florida

    Jacksonville, Florida · Recruiting

  • University of Miami Don Soffer Clinical Research Center

    Miami, Florida · Not yet recruiting

  • The Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic - Transplant Center - Rochester

    Rochester, Minnesota · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Atrium Health, Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Duke University Hospital

    Durham, North Carolina · Recruiting

  • Cleveland Clinic - Taussig Cancer Institute

    Cleveland, Ohio · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina (MUSC) - Hollings Cancer Center

    Charleston, South Carolina · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas · Recruiting

  • Oncology Consultants

    Houston, Texas · Recruiting

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington · Recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Not yet recruiting

  • University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital)

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu

    Nantes, France · Recruiting

  • Centre Hospitalier Universitaire de Poitiers (CHU de Poitiers)

    Poitiers, France · Recruiting

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, France · Recruiting

  • Universitaire de Lille

    Villeneuve-d'Ascq, France, France · Recruiting

  • Hospital ClÃ-nic de Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Instituto de Investigacion Biomedica de Salamanca (IBSAL)

    Salamanca, Spain · Recruiting

  • Clínica Universidad de Navarra

    Pamplona, Navarre, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.